REGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit
October 04 2016 - 4:16PM
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated virus (AAV) gene therapy based on its
proprietary NAV® Technology Platform, today announced that
President and CEO Kenneth T. Mills will present a company overview
at the Jefferies Gene Editing and Gene Therapy Summit. The company
presentation will take place on Tuesday, October 11, 2016, at 1:20
p.m. ET at the Jefferies Conference Center in New York City. In
addition, REGENXBIO representatives will be holding one-on-one
meetings at the conference.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the
development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV®
Technology Platform, a proprietary AAV gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to
transform the lives of patients suffering from severe diseases with
significant unmet medical need by developing and commercializing in
vivo gene therapy products based on REGENXBIO's NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a
combination of internal development efforts and third-party NAV
Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV
Technology Platform was being applied in the development of 29
product candidates for a variety of diseases, including five
internally developed candidates and 24 partnered candidates
developed by REGENXBIO's licensees.
CONTACT:
Investors
Elizabeth Broder, 646-378-2945
ebroder@troutgroup.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024